MammaPrint is a genomic test used to assess the risk of breast cancer recurrence in women with early-stage breast cancer. It analyzes the activity of 70 specific genes in tumor tissue to determine the likelihood of cancer recurrence and, thus, helps guide decisions about the necessity of chemotherapy.
The combination of MammaPrint with other clinical and pathological factors is considered a robust approach for making treatment decisions in breast cancer.
LOW-RISK PATIENTS HAVE
CHANCE OF RECURRENCE
The MINDACT trial determined that these patients do not benefit from chemotherapy.
HIGH-RISK PATIENTS HAVE
CHANCE OF RECURRENCE
These patients showed significantly better outcomes with chemotherapy.
Consider this test in the following cases:
The methodology used for this test is as follows:
Biopsy: In Paraffin Block or Slide
Up to 30 calendar days
Medical request.
Type |
Description |
Technique |
Microarray |
Accuracy |
85-90% |
Main Office Rua Bento Gonçalves, 59, Room 802 — Centro, Marau, RS — 99150-000
Porto Alegre Office Rua Gomes Jardim, 301 , Room 918/909 — Santana, Porto Alegre, RS — 90620-130